Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh

A Phase 2, Randomized, Observer-blind, Controlled, Age De-escalation, Dosage Escalation Study to Assess Safety and Immunogenicity of a Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine in Healthy Young Children, Infants, and Neonates in Bangladesh

The purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for neurovirulence of shed virus (secondary objective) of a novel oral polio type 1 vaccine, nOPV1, as compared to Sabin monovalent type 1 vaccine controls (mOPV1), in healthy young children (192 subjects), infants (336 subjects), and neonates (1155 subjects).

Study Overview

• Status: Recruiting
• Conditions: Poliomyelitis
• Intervention / Treatment: Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1)

Detailed Description

This single-center trial is is the first clinical assessment of nOPV1 in a pediatric population. It will be a 12-arm, randomized, observer-blind, controlled trial, with Sabin monovalent type 1 vaccine (mOPV1) serving as the control. Enrollment in this pediatric study will be staggered into three age-descending cohorts, Cohort 1 composed of 192 healthy young children 1 to less than 5 years of age who have completed their full routine polio immunization series, Cohort 2 composed of 336 healthy infants 6 weeks of age (+6 days) who will receive only one dose of inactivated poliomyelitis vaccine (IPV) on Day 1, and finally Cohort 3, composed of 1155 healthy poliomyelitis unvaccinated neonates (day of birth +3 days). Participants will receive two doses of either nOPV1 at dose levels of 10^5.5 CCID50, 10^6.0 CCID50 or 10^6.5 CCID50, or the mOPV control vaccine. The second dose of vaccine will be given 28 days following the first dose. In order to demonstrate the vaccine's ability to reduce fecal shedding following a challenge with the Sabin type 1 strain, the infant cohort will be challenged with mOPV 8 weeks after the second vaccine dose. Participants will be followed until 28 weeks (young children and neonates) or 32 weeks (infants) after their Day 1 vaccination.

• Study Type: Interventional
• Enrollment (Estimated): 1683
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Tushar Tewari, MD; Phone Number: +91 11 4064 0005; Email: ttewari@path.org

Study Locations

• Bangladesh
  • Dhaka, Bangladesh, 1212
    • Recruiting
    • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
    • Contact: K. Zaman, MBBS, MPH, PhD, FRCP; Phone Number: 3806 +880 2 9827001 10; Email: kzaman@icddrb.org
    • Principal Investigator: K. Zaman, MBBS, MPH, PhD, FRCP

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 4 years (Child)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria for all participants:

1. Healthy, as defined by the absence of any clinically significant medical condition or congenital anomaly as determined by medical history, physical examination, and clinical assessment of the investigator
2. Parent(s) or guardian(s) willing and able to provide written informed consent prior to performance of any study-specific procedure
3. Resides in study area and parent understands and is able and willing to adhere to all study visits and procedures (as evidenced by a signed informed consent form [ICF] and assessment by the investigator)
4. Parent agrees for participant to receive all routine infant and childhood immunizations as per the approved protocol-adjusted schedule

Inclusion Criteria for Cohort 1 (young children) participants only:

1. Male or female child from 1 to less than 5 years of age at the time of initial study vaccination
2. Based on documentation, previously received a 3 or 4 dose primary poliomyelitis immunization series containing OPV (may have also received IPV), with last dose received more than 3 months prior to initial study vaccination

Inclusion Criteria for Cohort 2 (infants) participants only:

1. Male or female infant expected to be 6 weeks of age (43rd to 49th day of life [with day of birth being the first day of life], inclusive+ 6-day window), at the time of initial study vaccination
2. Prior to study vaccination has received no doses of IPV or OPV, based on no evidence of such vaccination per available documentation.

Inclusion Criteria for Cohort 3 (neonates) participants only:

1. Male or female newborn (1st day of life+ 3-day window, inclusive), at the time of initial study vaccination
2. Prior to study vaccination has received no doses of IPV or OPV or rotavirus vaccine, based on no evidence of such vaccination per available documentation.

Exclusion Criteria for all participants:

1. For all participants, the presence of anyone under 10 years of age in the participant's household (living in the same house or apartment unit) who does not have complete "age appropriate" vaccination status with respect to poliovirus vaccines at the time of study vaccine administration. For household members younger than 10 years of age, "age appropriate" vaccination is complete series of trivalent Oral Poliovirus Vaccine (tOPV) or at least three doses of bivalent (types 1 and 3) Oral Poliovirus Vaccine (bOPV) plus a booster fractional dose of IPV (fractional dose Inactivated Polio Vaccine; fIPV).
2. For all participants, having a member of the participant's household (living in the same house or apartment unit) who has received OPV based on the vaccination records in the previous 3 months before study vaccine administration.
3. Any participating children attending day care or pre-school during their participation in the study until one month after their last study vaccine administration.
4. Moderate or severe (grade ≥ 2) acute illness at the time of enrollment/first study vaccination - temporary exclusion. Participant with mild (grade 1) acute illnesses may be enrolled at the discretion of the investigator.
5. Presence of fever on the day of enrollment/first study vaccination (axillary temperature ≥37.5˚C) - (Temporary exclusion for Cohorts 1 and 2)
6. A known allergy, hypersensitivity, or intolerance to any components of the study vaccines, including all macrolide and aminoglycoside antibiotics (e.g., erythromycin and kanamycin)
7. Evidence of a clinically significant congenital or genetic defect as judged by the investigator
8. History of chronic administration (defined as more than 14 days) of immunosuppressant medications, including corticosteroids (> 0.5mg/kg/day of prednisolone (or equivalent)). Topical and inhaler steroids are permitted (unless indicative of a significant chronic illness otherwise excluding the infant/young child)
9. Any self-reported known or suspected immunosuppressive or immunodeficiency condition (including HIV infection) in the participant or household member (living under the same roof/in the same building rather than in the same compound)
10. Receipt of any immune-modifying or immunosuppressant drugs prior to the first study vaccine dose or planned use during the study of study participants or a household member
11. Any known or suspected bleeding disorder in the participant that would pose a risk to venipuncture or intramuscular injection

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Quadruple

Number of Arms

12

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group 1: Young Children, nOPV1 10^5.5 CCID50; 48 young children aged 1 to <5 years will receive 2 doses of nOPV1 at a dose level of 10^5.5 CCID50 on Day 1 and Day 29	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
Experimental: Group 3: Young Children, nOPV1 10^6.0 CCID50; 48 young children aged 1 to <5 years will receive 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 1 and Day 29	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
Experimental: Group 5: Young Children, nOPV1 10^6.5 CCID50; 48 young children aged 1 to <5 years will receive 2 doses of nOPV1 at a dose level of 10^6.5 CCID50 on Day 1 and Day 29	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
Active Comparator: Groups 2, 4 and 6: Young Children, mOPV1; 48 young children aged 1 to <5 years will receive 2 doses of mOPV1 at a dose level of ≥ 10^6.0 CCID50 on Day 1 and Day 29	Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1); The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
Experimental: Group 7: Infants, nOPV1 10^5.5 CCID50; 96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10^5.5 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.; Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1); The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
Experimental: Group 9: Infants, nOPV1 10^6.0 CCID50; 96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.; Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1); The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
Experimental: Group 11: Infants, nOPV1 10^6.5 CCID50; 48 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.; Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1); The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
Active Comparator: Groups 8, 10 and 12: Infants, mOPV1; 96 infants aged 6 weeks (+6 days) will receive 1 dose of IPV on Day 1, then 2 doses of mOPV1 at a dose level of ≥ 10^6.0 CCID50 on Day 29 and Day 57, and a challenge dose of mOPV on Day 113.	Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1); The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.
Experimental: Group 13: Neonates, nOPV1 10^5.5 CCID50; 330 neonates (day of birth + 3 days) will receive 2 doses of nOPV1 at a dose level of 10^5.5 CCID50 on Day 1 and Day 29.	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
Experimental: Group 15: Neonates, nOPV1 10^6.0 CCID50; 330 neonates (day of birth + 3 days) will receive 2 doses of nOPV1 at a dose level of 10^6.0 CCID50 on Day 1 and Day 29.	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
Experimental: Group 17: Neonates, nOPV1 10^6.5 CCID50; 165 neonates (day of birth + 3 days) will receive 2 doses of nOPV1 at a dose level of 10^6.5 CCID50 on Day 1 and Day 29.	Biological: Novel Live Attenuated Type 1 Oral Poliomyelitis Vaccine (nOPV1); Each 0.1 mL (2 drops) dose of nOPV1 vaccine contains approximately 10^5.5, 10^6.0, or 10^6.5 CCID50.
Active Comparator: Groups 14, 16 and 18: Neonates, mOPV; 330 neonates (day of birth + 3 days) will receive 2 doses of mOPV1 at a dose level of ≥ 10^6.0 CCID50 on Day 1 and Day 29	Biological: Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1); The Sabin Monovalent Oral Poliomyelitis Vaccine Type 1 control and challenge vaccine (mOPV1) contains ≥ 10^6.0 CCID50 per 0.1 mL (2 drops) dose.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of serious adverse events (SAEs) from the time of first study vaccination through the end of the study	Serious adverse event is any adverse event that results in any of the following outcomes: Death; Is life-threatening (life-threatening means that the study participant was, in the opinion of the site PI or PATH, at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe).; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; Important medical event that may not result in one of the above outcomes but may jeopardize the health of the study participant and require medical or surgical intervention to prevent one of the outcomes listed in the above definition of serious adverse event	From Day 1 to end of study, up to Day 197 (young children and neonates) or Day 225 (infants)
Frequency of solicited adverse events (AEs) for 7 days (day of vaccination and 6 following days) after each vaccination	Solicited AEs are pre-specific AEs that are common or known to be associated with vaccination that are actively monitored as potential indicators of vaccine reactogenicity. The following specific solicited AEs will be monitored for this trial: Fever (axillary temperature ≥ 37.5°C); Vomiting; Diarrhea; Irritability; Decreased feeding or appetite; Fatigue or decreased activity	From vaccination to 7 days post vaccination
Frequency of unsolicited AEs for 28 days (day of vaccination and 27 following days) after each vaccination	Unsolicited AEs are any AEs reported spontaneously by the participant's parent, observed by the study personnel during study visits or identified during review of medical records or source documents. In the absence of a diagnosis, abnormal physical examination findings or abnormal clinical safety laboratory test results that are assessed by the investigator to be clinically significant will be reported as an AE.	From vaccination to 28 days post vaccination
Post-vaccination frequency of seroconversion of type 1 anti-polio serum neutralizing antibody (NAb).	Following two doses of nOPV1, at dose levels of 10^6.0 and 10^5.5 CCID50/dose, compared to mOPV1, in healthy neonates. For unvaccinated neonates, seroconversion will be defined as either a minimum 4-fold higher antibody titer relative to the expected level of maternal antibody and seropositivity (reciprocal titer ≥ 8) at the post-vaccination time point among those initially seropositive, or post-vaccination seropositivity among those initially seronegative.	28 days post second vaccination

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Post-vaccination frequency of seroconversion of type 1 anti-polio serum NAb.	At dose levels of 10^6.0 and 10^5.5 CCID50/dose following one dose in healthy neonates, and following one or two doses in healthy young children and infants at all dose levels, compared to mOPV1. For unvaccinated neonates, seroconversion will be defined as either a minimum 4-fold higher antibody titer relative to the expected level of maternal antibody and seropositivity (reciprocal titer ≥ 8) at the post-vaccination time point among those initially seropositive, or post-vaccination seropositivity among those initially seronegative. For previously vaccinated cohorts, seroconversion will be defined as either a minimum 4-fold rise in titer relative to the baseline value among those initially seropositive, or post-vaccination seropositivity among those seronegative at baseline.	Baseline and 28 days post vaccination (Day 1 and Day 29 for neonates; Day 29, Day 57 and Day 85 for infants; Day 1, Day 29 and Day 57 young children)
Median type 1 anti-polio serum NAb titers.	Elicited by nOPV1, compared to that of mOPV1, following one or two doses in healthy young children, infants, and neonates.	Baseline and 28 days post vaccination (Day 1, Day 29 and Day 57 for young children and neonates; Day 29, Day 57 and Day 85 for infants)
Type 1 anti-polio serum NAb Geometric Mean Titer (GMT).	Elicited by nOPV1, compared to that of mOPV1, following one or two doses in healthy young children, infants, and neonates.	Baseline and 28 days post vaccination (Day 1, Day 29 and Day 57 for young children and neonates; Day 29, Day 57 and Day 85 for infants)
Post-vaccination GMT ratios of type 1 anti-polio serum NAb, adjusted for baseline immunity.	Elicited by nOPV1, compared to that of mOPV1, following one or two doses in healthy young children, infants, and neonates.	Baseline and 28 days post vaccination (Day 1, Day 29 and Day 57 for young children and neonates; Day 29, Day 57 and Day 85 for infants)
Seroprotection rate, defined as type 1 anti-polio serum NAb reciprocal titer ≥ 8.	Elicited by nOPV1, compared to that of mOPV1, following one or two doses in healthy young children, infants, and neonates.	Baseline and 28 days post vaccination (Day 1, Day 29 and Day 57 for young children and neonates; Day 29, Day 57 and Day 85 for infants)
Geometric mean fold rise (GMFR) in NAb titer relative to baseline for post-dose-1 and relative to post-dose-1 for post-dose-2.	Elicited by nOPV1, compared to that of mOPV1, in healthy young children, infants, and neonates.	Baseline and 28 days post vaccination (Day 1, Day 29 and Day 57 for young children and neonates; Day 29, Day 57 and Day 85 for infants)
Proportion of participants shedding type 1 poliovirus at any and at each post-vaccination stool collection, as assessed by polymerase chain reaction (PCR) in infants and neonates.	After the initial dose of nOPV1, compared to mOPV1.	Baseline through to 28 days post initial vaccination (Day 29 through to Day 57 for infants; Day 1 through to Day 29 for neonates)
Proportion of participants shedding type 1 poliovirus at any and at each post-challenge stool collection, as assessed by PCR in infants.	In participants negative for type 1 poliovirus in their last pre-challenge stool sample.	Day of challenge through to 28 days post challenge (Day 113 through to Day 141, for infants)
Neurovirulence of shed study vaccine virus from select stool samples as measured by a transgenic mouse neurovirulence test in a subset of neonates.	Within 28 days of an initial nOPV dose and compared to that of mOPV1.	Baseline through to 28 days post initial vaccination (Day 1 through to Day 29 for neonates)

Collaborators and Investigators

• Sponsor: PATH
• Collaborators: Bill and Melinda Gates Foundation; Centers for Disease Control and Prevention; PT Bio Farma; DiagnoSearch Life Sciences Pvt. Ltd.
• Investigators: Principal Investigator: K. Zaman, MBBS, MPH, PhD, FRCP, International Centre for Diarrhoeal Disease Research, Bangladesh

Study record dates

Study Major Dates

• Study Start (Actual): March 27, 2023
• Primary Completion (Estimated): February 1, 2025
• Study Completion (Estimated): February 1, 2025

Study Registration Dates

• First Submitted: November 10, 2022
• First Submitted That Met QC Criteria: November 30, 2022
• First Posted (Actual): December 9, 2022

Study Record Updates

• Last Update Posted (Actual): February 22, 2024
• Last Update Submitted That Met QC Criteria: February 21, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Vaccine safety; Vaccine immunogenicity; Vaccine tolerability; Vaccine reactogenicity; Vaccine viral shedding
• Additional Relevant MeSH Terms: Central Nervous System Diseases; Nervous System Diseases; RNA Virus Infections; Virus Diseases; Infections; Neuromuscular Diseases; Central Nervous System Infections; Enterovirus Infections; Picornaviridae Infections; Spinal Cord Diseases; Myelitis; Neuroinflammatory Diseases; Poliomyelitis; Physiological Effects of Drugs; Immunologic Factors; Vaccines
• Other Study ID Numbers: CVIA 093

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No